SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 15 Apr, 2021  

Hyderabad.9.Thmb.jpg RICH shortlists startups under AID programme

Hyderabad.9.jpg
   Top Stories
» 49% Indian startups now from tier 2, 3 cities: Jitendra Singh
» 'India ranks 3rd in global startup ecosystem & number of unicorns'
» Tripura exported over 9K tonnes of pineapples in 2 years
» CPI inflation eases to 6.71% in July, IIP falls to 12.3%
» Rupee depreciates 12 paise to close at 79.64 against US dollar
SME Times News Bureau | 15 Apr, 2021
The Research and Innovation Circle of Hyderabad (RICH) on Thursday announced the shortlist of its first cohort of start-ups, selected under the Acceleration Initiative for Diagnostics (AID) programme, designed as a multi-stakeholder alliance to identify and nurture the best start-ups in the diagnostics space.

RICH-AID is aimed at building a strong ecosystem of start-ups, innovators, hospitals, clinicians and mentors to help start-ups get access to facilities, equipment and expertise, said RICH, an initiative of by the office of Principal Scientific Adviser (PSA) to the Central government and the Telangana government.

According to Invest India, the medical diagnostics market in India is estimated to grow at 20.4 per cent to reach $32 billion. Covid has accelerated the need for more diagnostics across all health sectors.

The programme has been developed out of a perceived need to address the challenges faced by start-ups in the rapidly growing med-tech domain-ranging from the inability to access equipment, clinical samples, and research expertise to a lack of mentorship and difficulties in outreach.

It will also help boost Hyderabad, which contributes roughly 35 per cent of the country's pharmaceutical output, as the pharma capital of India. RICH-AID will leverage the existence of India's largest med-tech park, a large number of research institutions, and over 15 life science incubators and other supporting facilities set up by Telangana.

"The Covid-19 pandemic has underlined the need for accelerated research in diagnostics followed by a rapid go-to-market for such innovations which can help us deal with such medical emergencies. In Hyderabad, we already have a fertile ecosystem of industry, hospitals, clinicians and mentors. With the AID programme, we hope to bring all of these together in a manner which can best help young innovators convert their ideas into viable business propositions. This cohort is just the first of many such start-ups we hope to engage with and help transform the diagnostics space not just in Hyderabad but across India," said Ajit Rangnekar, Director General, RICH.

Originally announced on January 28, the AID programme saw an enthusiastic response from entrepreneurs and start-ups across the med-tech ecosystem. A total of 76 applications were received from India, Canada, the US, and South Korea.

Ten of the startups were selected on the basis of a number of criteria such as solution USP, technical strength, usability and scalability, readiness, validation, fit for purpose, commercial roadmap after the entries were evaluated by a panel constituting thematic experts and industry leaders.
 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter